Elimination of Rubella and Congenital Rubella Syndrome in the Americas
Author(s) -
Carlos CastilloSolórzano,
Christina Marsigli,
Pamela BravoAlcántara,
Brendan Flannery,
Cuauhtémoc Ruíz Matus,
Gina Tambini,
Socorro Gross-Galiano,
Jon Kim Andrus
Publication year - 2011
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jir472
Subject(s) - rubella , measles , congenital rubella syndrome , medicine , rubella vaccine , vaccination , immunization , virology , congenital rubella , transmission (telecommunications) , pediatrics , immunology , antibody , engineering , electrical engineering
In 2003, the Pan American Health Organization (PAHO) adopted a resolution calling for rubella and congenital rubella syndrome (CRS) elimination in the Americas by the year 2010. To accomplish this goal, PAHO advanced a rubella and CRS elimination strategy including introduction of rubella-containing vaccines into routine vaccination programs accompanied by high immunization coverage, interruption of rubella transmission through mass vaccination of adolescents and adults, and strengthened surveillance for rubella and CRS. The rubella elimination strategies were aligned with the successful measles elimination strategies. By the end of 2009, all countries routinely vaccinated children against rubella, an estimated 450 million people had been vaccinated against measles and rubella in supplementary immunization activities, and rubella transmission had been interrupted. This article describes how the region eliminated rubella and CRS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom